Skip to main content
Fig. 3 | Critical Care

Fig. 3

From: Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients

Fig. 3

Mean cumulative amount (a) and infusion rate (b) of open-label norepinephrine over time in septic shock patients. Selepressin and placebo were infused at a constant rate as indicated, whereas norepinephrine was weaned as fast as possible while still keeping the target treatment mean arterial pressure ≥65 mmHg. Numbers at the bottom of the figure indicate number of patients at each time point. Bars indicate SD. Pl Placebo, 1.25 1.25 ng/kg/minute, 2.5 2.5 ng/kg/minute

Back to article page